No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No effect on tocilizumab is expected as it is an IL-6 receptor monoclonal antibody and likely undergoes elimination via binding to its target antigen. Emtricitabine and tenofovir disoproxil fumarate are eliminated renally.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking